Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial

To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. The trial design was a single-c...

Full description

Saved in:
Bibliographic Details
Published in:Health technology assessment (Winchester, England) Vol. 13; no. 27; pp. iii - iv
Main Authors: Hay, A D, Redmond, N M, Costelloe, C, Montgomery, A A, Fletcher, M, Hollinghurst, S, Peters, T J
Format: Journal Article
Language:English
Published: England NIHR Journals Library 01-05-2009
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. The trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately. There were three recruitment settings, as follows: 'local' where research nurses were recruited from NHS primary care sites; 'remote' where NHS sites notified the study of potentially eligible children; and 'community' where parents contacted the study in response to local media advertisements. Children aged between 6 months and 6 years with fever > or = 37.8 degrees C and < or = 41 degrees C due to an illness that could be managed at home. The intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4-6 hours (maximum of four doses in 24 hours) and ibuprofen every 6-8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child's weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose. For additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI -6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2-45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference -3 minutes, 95% CI 24-18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4-6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6-4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services:14 pounds [standard deviation (SD) 23 pounds] versus 20 pounds (SD 38 pounds) for paracetamol and 18 pounds (SD 40 pounds) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: 24 pounds (SD 46 pounds) versus 26 pounds (SD 63 pounds) for paracetamol and 30 pounds (SD 91 pounds) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were 'back to normal' by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified 'viral illness'. Young children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood.
AbstractList Objectives: To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. Design: The trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately. Setting: There were three recruitment settings, as follows: ‘local’ where research nurses were recruited from NHS primary care sites; ‘remote’ where NHS sites notified the study of potentially eligible children; and ‘community’ where parents contacted the study in response to local media advertisements. Participants: Children aged between 6 months and 6 years with fever ≥ 37.8°C and ≤ 41°C due to an illness that could be managed at home. Interventions: The intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4–6 hours (maximum of four doses in 24 hours) and ibuprofen every 6–8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child’s weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose. Results: For additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI –6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2–45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference –3 minutes, 95% CI 24–18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4–6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6–4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services: £14 [standard deviation (SD) £23] versus £20 (SD £38) for paracetamol and £18 (SD £40) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: £24 (SD £46) versus £26 (SD £63) for paracetamol and £30 (SD £91) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were ‘back to normal’ by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified ‘viral illness’. Conclusions: Young children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood. Trial registration: Current Controlled Trials ISRCTN 26362730.
OBJECTIVESTo establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. DESIGNThe trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately. SETTINGThere were three recruitment settings, as follows: 'local' where research nurses were recruited from NHS primary care sites; 'remote' where NHS sites notified the study of potentially eligible children; and 'community' where parents contacted the study in response to local media advertisements. PARTICIPANTSChildren aged between 6 months and 6 years with fever > or = 37.8 degrees C and < or = 41 degrees C due to an illness that could be managed at home. INTERVENTIONSThe intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4-6 hours (maximum of four doses in 24 hours) and ibuprofen every 6-8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child's weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose. RESULTSFor additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI -6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2-45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference -3 minutes, 95% CI 24-18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4-6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6-4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services:14 pounds [standard deviation (SD) 23 pounds] versus 20 pounds (SD 38 pounds) for paracetamol and 18 pounds (SD 40 pounds) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: 24 pounds (SD 46 pounds) versus 26 pounds (SD 63 pounds) for paracetamol and 30 pounds (SD 91 pounds) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were 'back to normal' by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified 'viral illness'. CONCLUSIONSYoung children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood.
To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for time without fever, and the relief of fever-associated discomfort in young children who can be managed at home. The trial design was a single-centre (multisite), individually randomised, blinded, three-arm trial comparing paracetamol and ibuprofen together with paracetamol or ibuprofen separately. There were three recruitment settings, as follows: 'local' where research nurses were recruited from NHS primary care sites; 'remote' where NHS sites notified the study of potentially eligible children; and 'community' where parents contacted the study in response to local media advertisements. Children aged between 6 months and 6 years with fever > or = 37.8 degrees C and < or = 41 degrees C due to an illness that could be managed at home. The intervention was the provision of, and advice to give, the medicines for up to 48 hours: paracetamol every 4-6 hours (maximum of four doses in 24 hours) and ibuprofen every 6-8 hours (maximum of three doses in 24 hours). Every parent received two bottles, with at least one containing an active medicine. Parents, research nurses and investigators were blinded to treatment allocation by the use of identically matched placebo medicines. The dose of medicine was determined by the child's weight: paracetamol 15 mg/kg and ibuprofen 10 mg/kg per dose. For additional time without fever in the first 4 hours, use of both medicines was superior to use of paracetamol alone [adjusted difference 55 minutes, 95% confidence interval (CI) 33 to 77 minutes; p < 0.001] and may have been as good as ibuprofen (adjusted difference 16 minutes, 95% CI -6 to 39 minutes; p = 0.2). Both medicines together cleared the fever 23 minutes (95% CI 2-45 minutes; p = 0.015) faster than paracetamol alone, but no faster than ibuprofen alone (adjusted difference -3 minutes, 95% CI 24-18 minutes; p = 0.8). For additional time without fever in the first 24 hours, both medicines were superior to paracetamol (adjusted difference 4.4 hours, 95% CI 2.4-6.3 hours; p < 0.001) or ibuprofen (adjusted difference 2.5 hours, 95% CI 0.6-4.5 hours; p = 0.008) alone. No reduction in discomfort or other fever-associated symptoms was found, although power was low for these outcomes. An exploratory analysis showed that children with higher discomfort levels had higher mean temperatures. No difference in adverse effects was observed between treatment groups. The recommended maximum number of doses of paracetamol and ibuprofen in 24 hours was exceeded in 8% and 11% of children respectively. Over the 5-day study period, paracetamol and ibuprofen together was the cheapest option for the NHS due to the lower use of health-care services:14 pounds [standard deviation (SD) 23 pounds] versus 20 pounds (SD 38 pounds) for paracetamol and 18 pounds (SD 40 pounds) for ibuprofen. Both medicines were also cheapest for parents because the lower use of health care services resulted in personal saving on travel costs and less time off work: 24 pounds (SD 46 pounds) versus 26 pounds (SD 63 pounds) for paracetamol and 30 pounds (SD 91 pounds) for ibuprofen. This more than compensated for the extra cost of medication. However, statistical evidence for these differences was weak due to lack of power. Overall, a quarter of children were 'back to normal' by 48 hours and one-third by day 5. Five (3%) children were admitted to hospital, two with pneumonia, two with bronchiolitis and one with a severe, but unidentified 'viral illness'. Young children who are unwell with fever should be treated with ibuprofen first, but the relative risks (inadvertently exceeding the maximum recommended dose) and benefits (extra 2.5 hours without fever) of using paracetamol plus ibuprofen over 24 hours should be considered. However, if two medicines are used, it is recommended that all dose times are carefully recorded to avoid accidentally exceeding the maximum recommended dose. Manufacturers should consider supplying blank charts for this purpose. Use of both medicines should not be discouraged on the basis of cost to either parents or the NHS. Parents and clinicians should be aware that fever is a relatively short-lived symptom, but may have more serious prognostic implications than the other common symptom presentations of childhood.
Author Fletcher, M
Costelloe, C
Hay, A D
Hollinghurst, S
Montgomery, A A
Peters, T J
Redmond, N M
Author_xml – sequence: 1
  givenname: A D
  surname: Hay
  fullname: Hay, A D
  organization: Academic Unit of Primary Health Care, NIHR National School for Primary Care Research, Department of Community Based Medicine, University of Bristol, Bristol, UK
– sequence: 2
  givenname: N M
  surname: Redmond
  fullname: Redmond, N M
– sequence: 3
  givenname: C
  surname: Costelloe
  fullname: Costelloe, C
– sequence: 4
  givenname: A A
  surname: Montgomery
  fullname: Montgomery, A A
– sequence: 5
  givenname: M
  surname: Fletcher
  fullname: Fletcher, M
– sequence: 6
  givenname: S
  surname: Hollinghurst
  fullname: Hollinghurst, S
– sequence: 7
  givenname: T J
  surname: Peters
  fullname: Peters, T J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19454182$$D View this record in MEDLINE/PubMed
BookMark eNpFkV1LHTEQhkOx1KMt-AskV8WbtflO1rsiVQ8IetFeh2wy8axkE5vNEfrvXT2nepUhPPMMM-8ROsglA0InlJxzTsmPTXOUM00-oRUjQnWiZ-IArShXqpNMm0N0NM-PhAiqJP2CDmkvpKCGrdDDvavOQ3NTSdjlgMdh-1RLhIxjqbhtALcKrk2QGy4RR3iGiseM_WZMoUK-eGPu178vb3BdBGUaZwjYl9xqSWkpWx1d-oo-R5dm-LZ_j9Gfq19LT3d7d72-_HnbeW5o68wgtddEkegphJ6IwQhJPfSghJFESso4eNA0BjkI1UdOgVHdQ9DS-AH4MVrvvKG4R_tUx8nVf7a40b59lPpgXW2jT2Cd19pLogQnUhgt3aCdcERyE3g_SL-4vu9cy0H-bmFudtnNQ0ouQ9nOVmmmCDN6Ac92oK9lnivE98GU2NeA7P-AFvR079wOE4QPcJ8IfwH5G4yC
CitedBy_id crossref_primary_10_1097_INF_0000000000002452
crossref_primary_10_1111_bcp_13173
crossref_primary_10_4094_jkachn_2010_16_1_30
crossref_primary_10_1002_prp2_925
crossref_primary_10_1002_14651858_CD011534_pub2
crossref_primary_10_1002_14651858_CD011534_pub3
crossref_primary_10_1177_1367493513496663
crossref_primary_10_1542_peds_2009_3352
crossref_primary_10_17795_zjrms_7952
crossref_primary_10_1016_S0031_3939_10_70072_X
crossref_primary_10_1007_s12663_013_0611_7
crossref_primary_10_1111_j_1365_2702_2010_03258_x
crossref_primary_10_1016_j_clinthera_2012_06_011
crossref_primary_10_21518_2079_701X_2018_11_158_161
crossref_primary_10_1111_j_1524_4733_2010_00788_x
crossref_primary_10_21518_2079_701X_2019_2_106_112
crossref_primary_10_4094_jkachn_2010_16_4_324
crossref_primary_10_1007_s10787_009_0016_x
crossref_primary_10_1007_s40258_022_00780_7
crossref_primary_10_1177_0009922816678818
crossref_primary_10_1007_s00431_013_2239_5
crossref_primary_10_21508_1027_4065_2020_65_3_153_159
crossref_primary_10_3109_03639045_2011_605141
crossref_primary_10_3389_fped_2019_00217
crossref_primary_10_1186_s13063_022_06187_y
crossref_primary_10_3310_hta24370
crossref_primary_10_1016_j_therap_2020_04_005
crossref_primary_10_1016_j_amjoto_2018_10_012
crossref_primary_10_1007_s40268_014_0052_x
crossref_primary_10_1111_apa_13566
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOA
DOI 10.3310/hta13270
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2046-4924
EndPage iv
ExternalDocumentID oai_doaj_org_article_ac77c50643054875ab7a4a0538d39b5c
10_3310_hta13270
19454182
Genre Multicenter Study
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Department of Health
– fundername: Department of Health
  grantid: 03/09/01
GroupedDBID ---
53G
5GY
ADBBV
ADDVE
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCNDV
CGR
CUY
CVF
CZQ
DIK
EBS
ECM
EIF
EJD
F5P
GROUPED_DOAJ
NPM
OK1
P2P
P6G
TR2
W2D
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c381t-8b57c7060fc1ed904b8451ce9e6485055123ece71fd5b469f31e2179ed758cbe3
IEDL.DBID DOA
ISSN 1366-5278
IngestDate Tue Oct 22 14:50:37 EDT 2024
Sat Jun 22 21:01:20 EDT 2024
Fri Aug 23 02:06:05 EDT 2024
Sun Jun 23 00:28:06 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 27
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c381t-8b57c7060fc1ed904b8451ce9e6485055123ece71fd5b469f31e2179ed758cbe3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
OpenAccessLink https://doaj.org/article/ac77c50643054875ab7a4a0538d39b5c
PMID 19454182
PQID 67260287
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_ac77c50643054875ab7a4a0538d39b5c
proquest_miscellaneous_67260287
crossref_primary_10_3310_hta13270
pubmed_primary_19454182
PublicationCentury 2000
PublicationDate 2009-May
2009-05-00
20090501
2009-05-01
PublicationDateYYYYMMDD 2009-05-01
PublicationDate_xml – month: 05
  year: 2009
  text: 2009-May
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Health technology assessment (Winchester, England)
PublicationTitleAlternate Health Technol Assess
PublicationYear 2009
Publisher NIHR Journals Library
Publisher_xml – name: NIHR Journals Library
References 19949176 - Evid Based Med. 2009 Dec;14(6):174
References_xml
SSID ssj0041651
Score 2.1845562
Snippet To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen separately for...
OBJECTIVESTo establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen...
Objectives: To establish the relative clinical effectiveness and cost-effectiveness of paracetamol plus ibuprofen compared with paracetamol and ibuprofen...
SourceID doaj
proquest
crossref
pubmed
SourceType Open Website
Aggregation Database
Index Database
StartPage iii
SubjectTerms Acetaminophen - administration & dosage
Acetaminophen - economics
Acetaminophen - therapeutic use
Analgesics, Non-Narcotic - administration & dosage
Analgesics, Non-Narcotic - economics
Analgesics, Non-Narcotic - therapeutic use
Child
Child, Preschool
Cost-Benefit Analysis
Double-Blind Method
Drug Therapy, Combination
Female
fever
Fever - drug therapy
fever-associated discomfort
Humans
ibuprofen
Ibuprofen - administration & dosage
Ibuprofen - economics
Ibuprofen - therapeutic use
Infant
Male
paracetamol
Title Paracetamol and ibuprofen for the treatment of fever in children: the PITCH randomised controlled trial
URI https://www.ncbi.nlm.nih.gov/pubmed/19454182
https://search.proquest.com/docview/67260287
https://doaj.org/article/ac77c50643054875ab7a4a0538d39b5c
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JTsMwELWgB8QFsRNWI3GN2jRObHNjaVUOoEqAxC3yMoZKJUE0-X_GWQoXxIVblORgzYz83pPHbwi5UH7uowYWItV2IUMIC7U0LjQSwcEDUKT95eTJI394Ebcjb5OzHPXle8Iae-AmcH1lODfeVQ0L05NrpbliCktH2FjqxNS77yDtxFSzByPLSNobVylKLS4a29kYuUz_rVSowPxw4h9AVPv1_04ya7AZb5KNliXSq2Z1W2QF8m2ydt-eg--Q16m3WYZSvRdzqnJLZ7ry07chp0hCKZI6uuwgp4WjDrBi6Syn3d3ty_qf6d3TzYQiWtkC0w2Wto3rc3ysx3nskufxCP8J25EJoUHoLUOhE268IY4zEVg5YFqwJDIgIWUCyQ7CewwGeORsolEZuzgCFCUSLOoGoyHeI728yOGA0KEdCiH5YOiUQQSTmjuDElYkkMRKWBaQ8y5-2UfjjJGhovAxzroYB-TaB3b53XtZ1y8ww1mb4eyvDAfkrEtLhsHwBxoqh6JaZClHNYaSLyD7Tba-FyJZwlA6Hf7HAo7IenOG5Nscj0mv_KzghKwubHVaV90XjePY3Q
link.rule.ids 315,782,786,866,2106,27933,27934
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Paracetamol+and+ibuprofen+for+the+treatment+of+fever+in+children%3A+the+PITCH+randomised+controlled+trial&rft.jtitle=Health+technology+assessment+%28Winchester%2C+England%29&rft.au=Hay%2C+A+D&rft.au=Redmond%2C+N+M&rft.au=Costelloe%2C+C&rft.au=Montgomery%2C+A+A&rft.date=2009-05-01&rft.eissn=2046-4924&rft.volume=13&rft.issue=27&rft.spage=iii&rft.epage=iv&rft_id=info:doi/10.3310%2Fhta13270&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1366-5278&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1366-5278&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1366-5278&client=summon